Search

(1) Background: The coronavirus disease 2019 (COVID-19) pandemic has proven challenging to the management of patients with cancer, particularly those receiving systemic therapy. This study aimed to evaluate the impact of COVID-19 on patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab. (2) Methods: Patients with unresectable HCC who started atezolizumab/bevacizumab treatment between June 2020 and December 2021 at a tertiary cancer center in Korea were included (n = 241) and classified according to their COVID-19 status and severity. (3) Results: Thirty-five (14.5%) patients with unresectable HCC were diagnosed with COVID-19 during atezolizumab/bevacizumab treatment; 26 (74.2%) and nine (25.7%) in the low- and high-severity groups, respectively. The high-severity group showed higher neutrophil-to-lymphocyte ratios and lactate dehydrogenase levels. Liver and kidney injuries were observed in 31.4% and 17.1% of total patients, respectively. Liver injury was more prominent in patients with pre-existing liver dysfunction at baseline, who were more prevalent in the high-severity group. Atezolizumab/bevacizumab treatment was delayed by a median of 0 (range, 0–21) day in the low-severity group and 12 (range, 0–35) days in the high-severity group. The high-severity group showed worse post-infection progression-free survival (1.1 vs. 4.8 months, p = 0.017) and overall survival (2.2 months vs. not reached, p = 0.004). (4) Conclusions: Patients with impaired liver function at baseline are more susceptible to high-severity COVID-19, which affects atezolizumab/bevacizumab treatment outcomes. [ABSTRACT FROM AUTHOR]

Summary Background Body mass index (BMI), waist circumference (WC), and even dual-energy X-ray absorptiometry (DXA) are used for obesity diagnosis. However, it is not known which DXA-derived index of obesity correlates best with BMI and/or WC and it is not clear whether such an index is accurate or not. Objectives The aim of this study is to show the relationship between anthropometric measurements (BMI, WC) and body fat indices from DXA and to determine which DXA indices are strongly related to BMI and WC. Subjects This study was based on data obtained from the Fourth and Fifth Korea National Health and Nutrition Examination Survey (KNHANES IV-V). DXA measurements were performed on survey subjects over 10 years old from July 2008 through to May 2011. Of these, 18 198 individuals, aged 19 years and older for whom DXA data were available, were included. Methods Weighted Pearson's correlated coefficients ( r ) were calculated among indices, according to sex, age group and menopause, and the coefficients were compared with each other. Results BMI correlates most with trunk body fat mass in kg ( r = 0.831) and then with total body fat in kg ( r = 0.774, P < 0.00043 for difference of r ). In the older age group, BMI correlates with total body fat mass ( r = 0.822) better than with trunk fat mass ( r = 0.817, P < 0.00043). WC correlates with trunk body fat mass most in both genders and all age groups (0.804 ≤ r ≤ 0.906). Correlations of BMI ( r = 0.645 for men, 0.689 for women) and WC ( r = 0.678 for men, 0.634 for women) to body fat percentages (%) were less robust than those to body fat mass. Conclusions BMI and WC reflect trunk and total body fat in kg more than body fat percentage derived by DXA. [ABSTRACT FROM AUTHOR]